IL278761B2 - Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors - Google Patents

Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Info

Publication number
IL278761B2
IL278761B2 IL278761A IL27876120A IL278761B2 IL 278761 B2 IL278761 B2 IL 278761B2 IL 278761 A IL278761 A IL 278761A IL 27876120 A IL27876120 A IL 27876120A IL 278761 B2 IL278761 B2 IL 278761B2
Authority
IL
Israel
Prior art keywords
ing
compound
propyl
ethyl
methyl
Prior art date
Application number
IL278761A
Other languages
English (en)
Hebrew (he)
Other versions
IL278761A (en
IL278761B1 (en
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of IL278761A publication Critical patent/IL278761A/en
Publication of IL278761B1 publication Critical patent/IL278761B1/en
Publication of IL278761B2 publication Critical patent/IL278761B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL278761A 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors IL278761B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672864P 2018-05-17 2018-05-17
PCT/US2019/032639 WO2019222483A1 (en) 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Publications (3)

Publication Number Publication Date
IL278761A IL278761A (en) 2021-01-31
IL278761B1 IL278761B1 (en) 2024-11-01
IL278761B2 true IL278761B2 (en) 2025-03-01

Family

ID=68541026

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278761A IL278761B2 (en) 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Country Status (11)

Country Link
US (1) US12083098B2 (https=)
EP (1) EP3793545A4 (https=)
JP (2) JP7471660B2 (https=)
KR (1) KR20210038429A (https=)
CN (1) CN112437663A (https=)
AU (1) AU2019271285B2 (https=)
BR (1) BR112020023422A2 (https=)
CA (1) CA3100381A1 (https=)
IL (1) IL278761B2 (https=)
MX (1) MX2020012331A (https=)
WO (1) WO2019222483A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020415440A1 (en) * 2019-12-26 2022-08-04 Actuate Therapeutics, Inc. Compounds for the treatment of myelofibrosis
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib
CN117981712B (zh) * 2023-07-24 2025-02-28 南京鼓楼医院 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622987C (en) 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
KR101862291B1 (ko) * 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
WO2014165851A1 (en) 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
EP3665176B1 (en) * 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077138A1 (en) * 2006-12-19 2008-06-26 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOEKE A BAARSMA ET AL:, GLYCOGEN SYNTHASE KINASE-3 (GSK-3)REGULATES TGF-[BETA]1-INDUCED DIFFERENTIATION OF PULMONARY FIBROBLASTS, 16 May 2013 (2013-05-16) *

Also Published As

Publication number Publication date
CN112437663A (zh) 2021-03-02
JP7471660B2 (ja) 2024-04-22
US12083098B2 (en) 2024-09-10
JP2024069221A (ja) 2024-05-21
US20210212988A1 (en) 2021-07-15
EP3793545A4 (en) 2022-04-06
KR20210038429A (ko) 2021-04-07
IL278761A (en) 2021-01-31
WO2019222483A1 (en) 2019-11-21
MX2020012331A (es) 2021-03-09
AU2019271285B2 (en) 2024-10-03
CA3100381A1 (en) 2019-11-21
EP3793545A1 (en) 2021-03-24
AU2019271285A1 (en) 2020-12-03
IL278761B1 (en) 2024-11-01
BR112020023422A2 (pt) 2021-02-17
JP2021523951A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
JP2024069221A (ja) グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
US20200338097A1 (en) Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions
CN110475554B (zh) 用于预防或治疗靶向鞘氨醇1-磷酸受体4的非酒精性脂肪性肝炎的组合物
US20190255042A1 (en) Application of hedgehog pathway inhibitor in treating fibrosis diseases
JP2016520130A (ja) 心臓疾患における新規治療戦略としてのｂｅｔ阻害
KR20190035960A (ko) 간 질환의 치료 방법
JP2015511632A (ja) メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
US11529324B2 (en) Use of Kv11.1 channel inhibitors for treatment of pulmonary hypertension
Li et al. Targeting intestinal epithelial cell–programmed necrosis alleviates tissue injury after intestinal ischemia/reperfusion in rats
JP2016536370A (ja) 新規製剤
JP2016536370A5 (https=)
US20250017934A1 (en) New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
US20250025466A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
AU2019338236B2 (en) A GABAA receptor ligand
US20140024683A1 (en) Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases
KR20100116177A (ko) 근골격-관련 장애의 치료에서 헤지호그 효능제의 용도
WO2023199010A1 (en) Treatment of muscle fibrosis
IL295452A (en) Use of cyclosporine analogues for treating fibrosis
JP7762224B2 (ja) 線維化症の予防または治療用薬学的組成物
WO2025077707A1 (zh) 用于自身免疫疾病治疗的s1pr4调节剂化合物及其应用